Spark Investment Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Spark Investment Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-34,500	Closed	-$164K	–	54
2020 Q2	$164K	Sell	34,500 -338,200	-91%	-$1.35M	0.6%	39
2020 Q1	$745K	Buy	372,700 +180,221	+94%	+$496K	0.4%	85
2019 Q4	$664K	Sell	192,479 -999	-0.5%	-$2.51K	0.08%	307
2019 Q3	$554K	Buy	193,478 +111,078	+135%	+$346K	0.07%	241
2019 Q2	$312K	Buy	82,400 +34,200	+71%	+$206K	0.02%	415
2019 Q1	$392K	Buy	+48,200	New	+$413K	0.02%	426
2018 Q3	–	Sell	-60,200	Closed	-$344K	–	668
2018 Q2	$344K	Buy	+60,200	New	+$331K	0.02%	487
2016 Q3	–	Sell	-181,800	Closed	-$516K	–	828
2016 Q2	$516K	Sell	181,800 -348,300	-66%	-$1.08M	0.05%	457
2016 Q1	$1.5M	Buy	530,100 +442,500	+505%	+$1.96M	0.15%	217
2015 Q4	$904K	Buy	+87,600	New	+$871K	0.12%	260
2014 Q4	–	Sell	-78,300	Closed	-$764K	–	697
2014 Q3	$764K	Sell	78,300 -33,600	-30%	-$412K	0.11%	259
2014 Q2	$1.43M	Buy	111,900 +58,800	+111%	+$572K	0.21%	166
2014 Q1	$561K	Buy	+53,100	New	+$566K	0.09%	325

Other funds holding BCRX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Spark Investment Management's BCRX Position: Q3 2020 in Review

Spark Investment Management sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2020, closing a stake of 34,500 shares — an estimated $164K sold.

Spark Investment Management first reported a position in BCRX in Q1 2014 and held it in 13 quarters. The position peaked at $1.5M in Q1 2016. 154 funds tracked by Wall St. Rank hold BCRX as of Q3 2020.

Spark Investment Management reported no remaining BioCryst Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Spark Investment Management sold 34,500 BioCryst Pharmaceuticals shares in Q3 2020, an estimated $164K.
Spark Investment Management first reported a position in BioCryst Pharmaceuticals in Q1 2014 and held it in 13 quarters.
Spark Investment Management's BioCryst Pharmaceuticals position peaked at $1.5M in Q1 2016.
154 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2020.

Based on Spark Investment Management's 13F filing for Q3 2020, filed 12 Nov 2020.